We use cookies for a better user experience. Read our Privacy Policy

I Agree

Gene Delivery System Market

Gene Delivery System Market (Delivery System - Viral Gene Delivery System (Adenovirus System, Lentivirus Vector, Retrovirus Vector, Adeno-associated Virus Vector, Sendai Virus Vector, Herpes Simplex Virus Vector, and Others) , Non-viral Gene Delivery System (Natural Organic Compounds, Physical Methods, and Chemical Methods) , Combined Hybrid System; Application - Infectious Diseases, Oncology, Ophthalmology, Urology, Diabetes, CNS; Route of Administration - Oral, Injectable, Inhalation, Transdermal, Ocular, Nasal, Topical) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Gene Delivery System Market: Snapshot

Gene delivery systems are used to deliver therapeutic drugs targeting a specific area. Gene delivery is a procedure that introduces foreign DNA into host cells. The global gene delivery system market was valued approximately US$ 2,227.8 Mn in 2016 and is anticipated to expand at a CAGR of over 7.8% from 2017 to 2025 to reach value of nearly US$ 4,281.0 Mn by 2025. Increase in demand for targeted therapies and rise in technological advancements are likely to fuel the global gene delivery system market from 2017 to 2025.

The global gene delivery system market is driven by increase in need for advanced technologies for targeted systems. Launch of new and advanced technologies, rise in demand for targeted and low dose frequency drug delivery, increase in investment in research & development, surge in demand for self-administration devices for home health care, and increase in prevalence of chronic life-threatening diseases are driving the global gene delivery system market. However, high cost of the treatment and increase in drug recalls due to stringent regulations in developed countries are likely to restrain the market. The global gene delivery system market is segmented according to delivery system, application, route of administration, and geography.

gene-delivery-system-market.jpg

According to delivery system, the global gene delivery system market is divided into viral gene delivery system, non-viral gene delivery system, and combined hybrid system. The viral gene delivery system is further classified into adenovirus system, lentivirus vector, retrovirus vector, adeno-associated virus vector, sendai virus vector, herpes simplex virus vector, and others. The non-viral gene delivery system is further segmented into natural organic compounds, physical methods, and chemical methods. In terms of revenue, the viral gene delivery system segment dominates the global gene delivery system market. Increase in demand for viral gene delivery systems for the treatment of genetic and acquired diseases caused by insertion or deletion of a gene drives the segment. The combined hybrid delivery system segment account for a small share of the market.

Based on application, the global gene delivery system market is segregated into infectious diseases, oncology, ophthalmology, urology, diabetes, CNS, and others. In terms of revenue, the oncology segment dominates the global gene delivery system market. Rise in incidence of cancer across all regions drives the global gene delivery systems market. According to WHO report (2017), around 1 in 6 deaths occurs due to cancer globally. CNS is the second largest segment boosting the market. Increase in incidence of neurological diseases is likely to drive the segment by 2025. According to EurekAlert, neurological disorders is a leading cause of death globally. Diabetes is also a chronic disease which affects majority of population across the globe. According to WHO report, in 2016, around 1% of total deaths occurred only due to diabetes in Japan.

In terms of route of administration, the global gene delivery system market is segmented into oral, injectable, inhalation, transdermal, ocular, nasal, topical, and others. The injectable segment dominates the global gene delivery system market. The oral and injectable segments together accounted for 62.4% share of the market in 2016. The injectable route of administration is used for rapid drug absorption. Especially, drugs with low oral bioavailability are administered through the intramuscular or subcutaneous route. Oral formulations are inexpensive as compared to other dosage forms. This route of drug administration allows sustained release of formulation to reduce the frequency of the medication. These are some of the factors driving the segment. The inhalation segment accounts for less share of the global gene delivery system market. Drugs targeted for the treatment of lung diseases such as bronchodilators and steroids can be inhaled to achieve rapid action. This is likely to boost the segment.

Based on geography, the global gene delivery system market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global gene delivery system market. North America and Europe together accounted for 72.4% share of the market in 2016. Rise in prevalence of chronic diseases in the U.S. and Europe and technological advancement in drug delivery systems are driving the global gene delivery market. Rise in prevalence of acute and chronic diseases in the U.S. drives demand for drug delivery systems in the country. According to WHO report (2016), cancer accounts for around 23% of total deaths in the U.S. Demand for drug and gene delivery system is increasing in the region due to increase in prevalence of several chronic diseases. According to WHO report 2016, around 40% of total death in Germany were caused by cardiovascular diseases. The global gene delivery system market in Asia Pacific is projected to expand at a rapid pace due to increase in prevalence of diseases and rise in investment of key players in this region. The market in Middle East & Africa is likely to expand at a sluggish pace.

Major players operating in the global gene delivery system market include Novartis AG, Amgen Inc., Oxford BioMedia plc, SIBIONO, Shanghai Sunway Biotech Co. Ltd., Pfizer Inc., Bayer AG, Johnson & Johnson Services Inc., Human Stem Cells Institue, and Epeius Biotechnologies Corporation. These players adopt organic and in-organic growth strategies to expand their product offerings, expand geographically, increase customer base, and garner market share.

 

The global gene delivery system market has been segmented as follows:

by Delivery System

  • Viral Gene Delivery
    • Adenovirus Vector
    • Lentivirus Vector
    • Retrovirus Vector
    • Adeno-associated Virus Vector
    • Sendai Virus Vector
    • Herpes Simplex Virus Vector
    • Others
  • Non-viral Gene Delivery
    • Natural Organic Compounds
    • Physical Methods
    • Chemical Methods
  • Combined Hybrid Delivery System

by Application

  • Infectious Diseasess
  • Oncology
  • Ophthalmology
  • Urology
  • Diabetes
  • CNS
  • Others

by Route of Administration

  • Oral
  • Injectable
  • Inhalation
  • Transdermal
  • Ocular
  • Nasal
  • Topical

by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • China
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • Israel
    • South Africa
    • Rest of MEA
Gene Delivery System Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Gene Delivery System Market

4. Market Overview
     4.1. Introduction
            4.1.1. Delivery System Definition
     4.2. Overview
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunities
     4.5. Global Gene Delivery System Market Analysis and Forecasts, 2015–2025
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Porter’s Five Force Analysis
     4.7. Market Outlook
     4.8. Technological Advancements in Gene Delivery Products
     4.9. Regulatory Scenario
     4.10. Gene Therapy Pipeline Molecules

5. Global Gene Delivery System Market Analysis and Forecasts, by Delivery System
     5.1. Introduction & Definition
     5.2. Key Findings
     5.4. Market Value Forecast by Delivery System, 2015–2025
            5.4.1. Viral Gene Delivery
                     5.4.1.1. Adenovirus Vector
                     5.4.1.2. Lentivirus Vector
                     5.4.1.3. Retrovirus Vector
                     5.4.1.4. Adeno-associated Virus Vector
                     5.4.1.5. Sendai Virus Vector
                     5.4.1.6. Herpes Simplex Virus Vector
                     5.4.1.7. Others
            5.4.2. Non-viral Gene Delivery
                     5.4.2.1. Natural Organic Compounds
                     5.4.2.2. Physical Methods
                     5.4.2.3. Chemical Methods
            5.4.3. Combined Hybrid Delivery System
     5.5. Market Attractiveness by Delivery System

6. Global Gene Delivery System Market Analysis and Forecasts, by Application
     6.1. Introduction & Definition
     6.2. Key Findings
     6.4. Market Value Forecast by Application, 2015–2025
            6.4.1. Infectious Diseases
            6.4.2. Oncology
            6.4.3. Ophthalmology
            6.4.4. Urology
            6.4.5. Diabetes
            6.4.6. CNS
            6.4.7. Others
     6.5. Market Attractiveness by Application

7. Global Gene Delivery System Market Analysis and Forecasts, by Route of Administration
     7.1. Introduction & Definition
     7.2. Key Findings
     7.4. Market Value Forecast by Route of Administration, 2015–2025
            7.4.1. Oral
            7.4.2. Injectable
            7.4.3. Inhalation
            7.4.4. Transdermal
            7.4.5. Ocular
            7.4.6. Nasal
            7.4.7. Topical
     7.5. Market Attractiveness by Route of Administration

8. Global Gene Delivery System Market Analysis and Forecasts, by Region
     8.1. Key Findings
     8.2. Market Value Forecast by Region
            8.2.1. North America
            8.2.2. Europe
            8.2.3. Asia Pacific
            8.2.4. Latin America
            8.2.5. Middle East & Africa
     8.3. Market Attractiveness by Region

9. North America Gene Delivery System Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
     9.2. Market Value Forecast by Delivery System, 2015–2025
            9.2.1. Viral Gene Delivery
                     9.2.1.1. Adenovirus Vector
                     9.2.1.2. Lentivirus Vector
                     9.2.1.3. Retrovirus Vector
                     9.2.1.4. Adeno-associated Virus Vector
                     9.2.1.5. Sendai Virus Vector
                     9.2.1.6. Herpes Simplex Virus Vector
                     9.2.1.7. Others
            9.2.2. Non-viral Gene Delivery
                     9.2.2.1. Natural Organic Compounds
                     9.2.2.2. Physical Methods
                     9.2.2.3. Chemical Methods
            9.2.3. Combined Hybrid Delivery System
     9.3. Market Value Forecast by Application, 2015–2025
            9.3.1. Infectious Diseases
            9.3.2. Oncology
            9.3.3. Ophthalmology
            9.3.4. Urology
            9.3.5. Diabetes
            9.3.6. CNS
            9.3.7. Others
     9.4. Market Value Forecast by Route of Administration, 2015–2025
            9.4.1. Oral
            9.4.2. Injectable
            9.4.3. Inhalation
            9.4.4. Transdermal
            9.4.5. Ocular
            9.4.6. Nasal
            9.4.7. Topical
     9.5. Market Value Forecast by Country, 2015–2025
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis
            9.6.1. by Delivery System
            9.6.2. by Application
            9.6.3. by Route of Administration
            9.6.4. by Country

10. Europe Gene Delivery System Market Analysis and Forecast
     10.1.Introduction
            10.1.1. Key Findings
     10.2.Market Value Forecast by Delivery System, 2015–2025
            10.2.1. Viral Gene Delivery
                     10.2.1.1. Adenovirus Vector
                     10.2.1.2. Lentivirus Vector
                     10.2.1.3. Retrovirus Vector
                     10.2.1.4. Adeno-associated Virus Vector
                     10.2.1.5. Sendai Virus Vector
                     10.2.1.6. Herpes Simplex Virus Vector
                     10.2.1.7. Others
            10.2.2. Non-viral Gene Delivery
                     10.2.2.1. Natural Organic Compounds
                     10.2.2.2. Physical Methods
                     10.2.2.3. Chemical Methods
            10.2.3. Combined Hybrid Delivery System
     10.3.Market Value Forecast by Application, 2015–2025
            10.3.1. Infectious Diseases
            10.3.2. Oncology
            10.3.3. Ophthalmology
            10.3.4. Urology
            10.3.5. Diabetes
            10.3.6. CNS
            10.3.7. Others
     10.4.Market Value Forecast by Route of Administration, 2015–2025
            10.4.1. Oral
            10.4.2. Injectable
            10.4.3. Inhalation
            10.4.4. Transdermal
            10.4.5. Ocular
            10.4.6. Nasal
            10.4.7. Topical
     10.5.Market Value Forecast by Country/Sub-region, 2015–2025
            10.5.1. Germany
            10.5.2. U.K.
            10.5.3. France
            10.5.4. Spain
            10.5.5. Italy
            10.5.6. Rest of Europe
     10.6.Market Attractiveness Analysis
            10.6.1. by Delivery System
            10.6.2. by Application
            10.6.3. by Route of Administration
            10.6.4. by Country/Sub-region

11. Asia Pacific Gene Delivery System Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
     11.2.Market Value Forecast by Delivery System, 2015–2025
            11.2.1. Viral Gene Delivery
                     11.2.1.1. Adenovirus Vector
                     11.2.1.2. Lentivirus Vector
                     11.2.1.3. Retrovirus Vector
                     11.2.1.4. Adeno-associated Virus Vector
                     11.2.1.5. Sendai Virus Vector
                     11.2.1.6. Herpes Simplex Virus Vector
                     11.2.1.7. Others
            11.2.2. Non-viral Gene Delivery
                     11.2.2.1. Natural Organic Compounds
                     11.2.2.2. Physical Methods
                     11.2.2.3. Chemical Methods
            11.2.3. Combined Hybrid Delivery System
     11.3.Market Value Forecast by Application, 2015–2025
            11.3.1. Infectious Diseases
            11.3.2. Oncology
            11.3.3. Ophthalmology
            11.3.4. Urology
            11.3.5. Diabetes
            11.3.6. CNS
            11.3.7. Others
     11.4.Market Value Forecast by Route of Administration, 2015–2025
            11.4.1. Oral
            11.4.2. Injectable
            11.4.3. Inhalation
            11.4.4. Transdermal
            11.4.5. Ocular
            11.4.6. Nasal
            11.4.7. Topical
     11.5.Market Value Forecast by Country/Sub-region, 2015–2025
            11.5.1. Japan
            11.5.2. China
            11.5.3. India
            11.5.4. Australia and New Zealand
            11.5.5. Rest of Asia Pacific
     11.6.Market Attractiveness Analysis
            11.6.1. by Delivery System
            11.6.2. by Application
            11.6.3. by Route of Administration
            11.6.4. by Country

12. Latin America Gene Delivery System Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2.Market Value Forecast by Delivery System, 2015–2025
            12.2.1. Viral Gene Delivery
                     12.2.1.1. Adenovirus Vector
                     12.2.1.2. Lentivirus Vector
                     12.2.1.3. Retrovirus Vector
                     12.2.1.4. Adeno-associated Virus Vector
                     12.2.1.5. Sendai Virus Vector
                     12.2.1.6. Herpes Simplex Virus Vector
                     12.2.1.7. Others
            12.2.2. Non-viral Gene Delivery
                     12.2.2.1. Natural Organic Compounds
                     12.2.2.2. Physical Methods
                     12.2.2.3. Chemical Methods
            12.2.3. Combined Hybrid Delivery System
     12.3.Market Value Forecast by Application, 2015–2025
            12.3.1. Infectious Diseases
            12.3.2. Oncology
            12.3.3. Ophthalmology
            12.3.4. Urology
            12.3.5. Diabetes
            12.3.6. CNS
            12.3.7. Others
     12.4.Market Value Forecast by Route of Administration, 2015–2025
            12.4.1. Oral
            12.4.2. Injectable
            12.4.3. Inhalation
            12.4.4. Transdermal
            12.4.5. Ocular
            12.4.6. Nasal
            12.4.7. Topical
     12.5.Market Value Forecast by Country/Sub-region, 2015–2025
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6.Market Attractiveness Analysis
            12.6.1. by Delivery System
            12.6.2. by Application
            12.6.3. by Route of Administration
            12.6.4. by Country/Sub-region

13. Middle East & Africa Gene Delivery System Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2.Market Value Forecast by Delivery System, 2015–2025
            13.2.1. Viral Gene Delivery
                     13.2.1.1. Adenovirus Vector
                     13.2.1.2. Lentivirus Vector
                     13.2.1.3. Retrovirus Vector
                     13.2.1.4. Adeno-associated Virus Vector
                     13.2.1.5. Sendai Virus Vector
                     13.2.1.6. Herpes Simplex Virus Vector
                     13.2.1.7. Others
            13.2.2. Non-viral Gene Delivery
                     13.2.2.1. Natural Organic Compounds
                     13.2.2.2. Physical Methods
                     13.2.2.3. Chemical Methods
            13.2.3. Combined Hybrid Delivery System
     13.3.Market Value Forecast by Application, 2015–2025
            13.3.1. Infectious Diseases
            13.3.2. Oncology
            13.3.3. Ophthalmology
            13.3.4. Urology
            13.3.5. Diabetes
            13.3.6. CNS
            13.3.7. Others
     13.4.Market Value Forecast by Route of Administration, 2015–2025
            13.4.1. Oral
            13.4.2. Injectable
            13.4.3. Inhalation
            13.4.4. Transdermal
            13.4.5. Ocular
            13.4.6. Nasal
            13.4.7. Topical
     13.5.Market Value Forecast by Country/Sub-region, 2015–2025
            13.5.1. South Africa
            13.5.2. UAE
            13.5.3. Saudi Arabia
            13.5.4. Rest of Middle East & Africa
     13.6.Market Attractiveness Analysis
            13.6.1. by Delivery System
            13.6.2. by Application
            13.6.3. by Route of Administration
            13.6.4. by Country/Sub-region

14. Competition Landscape
     14.1.Market Player – Competition Matrix (by Tier and Size of Companies)
     14.2.Market Share Analysis by Company (2016)
     14.3.Company Profiles (Overview, Financials, Recent Developments, Strategy)
            14.3.1. Novartis AG
                     14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.1.2. Financial Overview
                     14.3.1.3. Product Portfolio
                     14.3.1.4. SWOT Analysis
                     14.3.1.5. Strategic Overview
            14.3.2. Amgen Inc.
                     14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.2.2. Financial Overview
                     14.3.2.3. Product Portfolio
                     14.3.2.4. SWOT Analysis
                     14.3.2.5. Strategic Overview
            14.3.3. Oxford BioMedia plc.
                     14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.3.2. Financial Overview
                     14.3.3.3. Product Portfolio
                     14.3.3.4. SWOT Analysis
                     14.3.3.5. Strategic Overview
            14.3.4. SIBIONO
                     14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.4.2. Financial Overview
                     14.3.4.3. Product Portfolio
                     14.3.4.4. SWOT Analysis
                     14.3.4.5. Strategic Overview
            14.3.5. Shanghai Sunway Biotech Co. Ltd.
                     14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.5.2. Financial Overview
                     14.3.5.3. Product Portfolio
                     14.3.5.4. SWOT Analysis
                     14.3.5.5. Strategic Overview
            14.3.6. Pfizer Inc.
                     14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.6.2. Financial Overview
                     14.3.6.3. Product Portfolio
                     14.3.6.4. SWOT Analysis
                     14.3.6.5. Strategic Overview
            14.3.7. Bayer AG
                     14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.7.2. Financial Overview
                     14.3.7.3. Product Portfolio
                     14.3.7.4. SWOT Analysis
                     14.3.7.5. Strategic Overview
            14.3.8. Johnson & Johnson Services Inc.
                     14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.8.2. Financial Overview
                     14.3.8.3. Product Portfolio
                     14.3.8.4. SWOT Analysis
                     14.3.8.5. Strategic Overview
            14.3.9. Human Stem Cells Institute
                     14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.9.2. Financial Overview
                     14.3.9.3. Product Portfolio
                     14.3.9.4. SWOT Analysis
                     14.3.9.5. Strategic Overview
            14.3.10. Epeius Biotechnologies Corporation
                     14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.10.2. Financial Overview
                     14.3.10.3. Product Portfolio
                     14.3.10.4. SWOT Analysis
                     14.3.10.5. Strategic Overview

List of Tables 

Table 01: Regulatory Scenario in Different Countries
Table 02: Gene Therapy Pipeline Molecules
Table 03: Drug Therapy Pipeline Products
Table 04: Global Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2015–2025
Table 05: Global Gene Delivery Systems Market Size (US$ Mn) Forecast, by Viral Gene Delivery, 2015–2025
Table 06: Global Gene Delivery Systems Market Size (US$ Mn) Forecast, by Non-viral Gene Delivery, 2015–2025
Table 07: Global Gene Delivery System Market Value (US$ Mn) Forecast, by Application, 2015–2025
Table 08: Global Gene Delivery Systems Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 09: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 10: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 11: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2015–2025
Table 12: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Viral Gene Delivery, 2015–2025
Table 13: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Non-viral Gene Delivery, 2015–2025
Table 14: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 15: North America Gene Delivery System Market Size (US$ Bn) Forecast, by Route of Administration, 2015–2025
Table 16: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 17: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2015–2025
Table 18: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Viral Gene Delivery, 2015–2025
Table 19: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Non-viral Gene Delivery, 2015–2025
Table 20: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 21: Europe Gene Delivery System Market Size (US$ Bn) Forecast, by Route of Administration, 2015–2025
Table 22: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 23: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2015–2025
Table 24: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Viral Gene Delivery, 2015–2025
Table 25: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Non-viral Gene Delivery, 2015–2025
Table 26: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 27: Asia Pacific Gene Delivery System Market Size (US$ Bn) Forecast, by Route of Administration, 2015–2025
Table 28: Latin America Gene Delivery System Market Size (US$ Bn) Forecast, by Country/Sub-region, 2015–2025
Table 29: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2015–2025
Table 30: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Viral Gene Delivery, 2015–2025
Table 31: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Non-viral Gene Delivery, 2015–2025
Table 32: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 33: Latin America Gene Delivery System Market Size (US$ Bn) Forecast, by Route of Administration, 2015–2025
Table 34: Middle East & Africa Gene Delivery System Market Size (US$ Bn) Forecast, by Country/Sub-region, 2015–2025
Table 35: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2015–2025
Table 36: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Viral Gene Delivery, 2015–2025, 2015–2025
Table 37: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Non-viral Gene Delivery, 2015–2025
Table 38: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 39: Middle East & Africa Gene Delivery System Market Size (US$ Bn) Forecast, by Route of Administration, 2015–2025

List of Figures

Figure 01: Global Gene Delivery System Market Snapshot
Figure 02: Global Gene Delivery System Market Size, by Route of Administration (US$ Bn), 2016
Figure 03: Global Gene Delivery System Market Size (US$ Mn), by Region, 2016 and 2025
Figure 04: Global Gene Delivery System Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 05: Global Gene Delivery System Market Value Share Analysis, by Type of Delivery System (2016)
Figure 06: Global Gene Delivery System Market Value Share Analysis, by Application (2016)
Figure 07: Global Gene Delivery System Market Value Share Analysis, by Route of Administration (2016)
Figure 08: Global Gene Delivery Systems Market Value Share, by Delivery System, 2016 and 2025
Figure 09: Global Viral Gene Delivery Systems Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 10: Global Non-viral Gene Delivery Systems Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 11: Global Combined Hybrid Systems Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 12: Global Gene Delivery Systems Market Attractiveness, by Delivery System, 2017–2025
Figure 13: Global Gene Delivery System Market Value Share Analysis, by Application, 2016 and 2025
Figure 14: Global Infectious Diseases Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 15: Global Oncology Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 16: Global Ophthalmology Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 17: Global Urology Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 18: Global Diabetes Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 19: Global CNS Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 20: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 21: Global Gene Delivery System Market Attractiveness, by Application, 2017–2025
Figure 22: Global Gene Delivery Systems Market Value Share, by Route of Administration, 2016 and 2025
Figure 23: Global Oral Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 24: Global Injectable Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 25: Global Inhalation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 26: Global Transdermal Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 27: Global Ocular Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 28: Global Nasal Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 29: Global Topical Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 30: Global Gene Delivery Systems Market Attractiveness, by Route of Administration, 2017–2025
Figure 31: Global Gene Delivery System Market Value Share Analysis, by Region, 2016 and 2025
Figure 32: Global Gene Delivery System Market Attractiveness, by Region, 2017–2025
Figure 33: North America Gene Delivery System Market Size (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 34: North America Gene Delivery System Market Value Share Analysis, by Country, 2016 and 2025
Figure 35: North America Gene Delivery System Market Attractiveness Analysis, by Country, 2017–2025
Figure 36: North America Gene Delivery System Market Value Share Analysis, by Delivery System, 2016 and 2025
Figure 44: North America Gene Delivery System Market Value Share Analysis, by Viral Gene Delivery, 2016 and 2025
Figure 37: North America Gene Delivery System Market Value Share Analysis, by Non-viral Gene Delivery, 2016 and 2025
Figure 38: North America Gene Delivery System Market Value Share Analysis, by Application, 2016 and 2025
Figure 39: North America Drug and Gene Delivery System Market Attractiveness Analysis, by Application, 2017–2025
Figure 40: North America Gene Delivery System Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 41: North America Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 42: Europe Gene Delivery System Market Size (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 43: Europe Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 44: Europe Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 45: Europe Drug and Gene Delivery System Market Value Share Analysis, by Gene Delivery System, 2016 and 2025
Figure 46: Europe Gene Delivery System Market Value Share Analysis, by Viral Gene Delivery, 2016 and 2025
Figure 47: Europe Gene Delivery System Market Value Share Analysis, by Non-viral Gene Delivery, 2016 and 2025
Figure 48: Europe Gene Delivery System Market Value Share Analysis, by Application, 2016 and 2025
Figure 49: Europe Gene Delivery System Market Attractiveness Analysis, by Application, 2016 and 2025
Figure 50: Europe Gene Delivery System Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 51: Europe Gene Delivery System Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 52: Asia Pacific Gene Delivery System Market Size (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 53: Asia Pacific Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 54: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 55: Asia Pacific Gene Delivery System Market Value Share Analysis, by Delivery System, 2016 and 2025
Figure 56: Asia Pacific Gene Delivery System Market Value Share Analysis, by Viral Gene Delivery, 2016 and 2025
Figure 57: Asia Pacific Gene Delivery System Market Value Share Analysis, by Non-viral Gene Delivery, 2016 and 2025
Figure 58: Asia Pacific Gene Delivery System Market Value Share Analysis, by Application, 2016 and 2025
Figure 59: Asia Pacific Drug Delivery System Market Attractiveness Analysis, by Application, 2017–2025
Figure 60: Asia Pacific Gene Delivery System Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 61: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 62: Latin America Gene Delivery System Market Size (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 63: Latin America Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 64: Latin America Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 65: Latin America Gene Delivery System Market Value Share Analysis, by Gene Delivery System, 2016 and 2025
Figure 66: Latin America Gene Delivery System Market Value Share Analysis, by Viral Gene Delivery, 2016 and 2025
Figure 67: Latin America Gene Delivery System Market Value Share Analysis, by Non-viral Gene Delivery, 2016 and 2025
Figure 68: Latin America Gene Delivery System Market Value Share Analysis, by Application, 2016 and 2025
Figure 69: Latin America Gene Delivery System Market Attractiveness Analysis, by Application, 2017–2025
Figure 69: Latin America Gene Delivery System Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 70: Latin America Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 71: Middle East & Africa Gene Delivery System Market Size (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 72: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Country/Sub-Region, 2016 and 2025
Figure 73: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Country/Sub-Region, 2017–2025
Figure 74: Middle East & Gene Delivery System Market Value Share Analysis, by Gene Delivery System, 2016 and 2025
Figure 75: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Viral Gene Delivery, 2016 and 2025
Figure 76: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Non-viral Gene Delivery, 2016 and 2025
Figure 77: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Application, 2016 and 2025
Figure 78: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Application, 2017–2025
Figure 79: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 80: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2017–2025

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

816

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved